For the year ending 2025-12-31, INTI has $2,511,307 in assets. $3,803,219 in debts. $2,375,493 in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 2,375,493 | |||
| Prepaid expenses and other assets | 71,507 | |||
| Total current assets | 2,447,000 | |||
| Operating lease right-of-use assets | 64,307 | |||
| Total assets | 2,511,307 | |||
| Accounts payable | 51,521 | |||
| Accrued expenses and other liabilities | 690,085 | |||
| Current portion of operating lease obligations | 24,724 | |||
| Total current liabilities | 766,330 | |||
| Deferred revenue | 3,000,000 | |||
| Operating lease obligations, less current portion | 36,889 | |||
| Total liabilities | 3,803,219 | |||
| Common stock, 0.0001 par value 500,000,000 shares authorized 172,573,545 and 172,323,545 shares issued and outstanding at december 31, 2025 and december 31, 2024, respectively | 17,257 | |||
| Additional paid-in capital | 54,110,425 | |||
| Accumulated deficit | -55,419,594 | |||
| Total stockholders (deficit) equity | -1,291,912 | |||
| Total liabilities and stockholders (deficit) equity | 2,511,307 | |||
Inhibitor Therapeutics, Inc. (INTI)
Inhibitor Therapeutics, Inc. (INTI)